59 Views | 10 Downloads
Jill R. Krissberg, jkrissbe@stanford.edu
Research idea, study design: J.R.K., M.E.H., and M.M.O. with input from all the listed authors. Data acquisition and statistical analysis: M.E.H. Data interpretation: all authors. Supervision: M.E.H. and M.M.O. Each author contributed to important intellectual content during the manuscript drafting or revisions, accepts personal accountability for the author's own contributions, and agrees to ensure that the questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Funding for the CureGN consortium is provided by U24DK100845 (formerly UM1DK100845), U01DK100846 (formerly UM1DK100846), U01DK100876 (formerly UM1DK100876), U01DK100866 (formerly UM1DK100866), and U01DK100867 (formerly UM1DK100867) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International. Dates of funding for the first phase of CureGN were from September 16, 2013 to May 31, 2019. Dr. Krissberg is a Tashia and John Morgridge Endowed Postdoctoral Fellow of the Stanford Maternal and Child Health Research Institute. Dr. Nestor reports support by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant No. TL1TR001875. Dr. Kopp is supported by the Intramural Research Program, NIDDK, NIH.
Dr. Greenbaum reports receiving research support from Vertex Pharmaceuticals, Apellis Pharmaceuticals, Reata Pharmaceuticals, Alexion Pharmaceuticals, and an honorarium from Alexion Pharmaceuticals. Dr. Almaani is a consultant for Aurinia Pharmaceuticals Inc. Dr. Reidy is a primary investigator for Complexa and Advicenne studies unrelated to this current manuscript. Dr. Gibson holds advisory roles for Aurinia Inc., Reata Inc., and Retrophin, Inc. Dr. Tuttle has received the research support from Goldfinch Bio and Travere/Retrophin and holds an advisory role for Goldfinch Bio. Dr. Sperati reports receiving research support for clinical trials from Alexion Pharmaceuticals and Alnylam, and honoraria for serving as chair of DSMB. All other authors declare that they have no known competing financial interests personal relationships that could appear to influence the work reported in this manuscript. Results of this manuscript have not been published previously in whole or part, with the exception of abstract format (ASN Kidney Week 2019).
Funding for the CureGN consortium is provided by U24DK100845 (formerly UM1DK100845), U01DK100846 (formerly UM1DK100846), U01DK100876 (formerly UM1DK100876), U01DK100866 (formerly UM1DK100866), and U01DK100867 (formerly UM1DK100867) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International.
© 2021 by The Author(s). Published by S. Karger AG, Basel